Pharmacokinetics of VP16-213 given by different administration methods
- 1 April 1982
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 7 (2-3), 141-145
- https://doi.org/10.1007/bf00254536
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- In vitro cytotoxicity of VP 16 on primary tumor and metastasis of Lewis lung carcinomaEuropean Journal of Cancer and Clinical Oncology, 1982
- Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1980
- Anti-tumour activity of the epipodophyllin derivative VP16–213 (etoposide: NSC-141540) in gestational choriocarcinomaEuropean Journal of Cancer (1965), 1980
- Podophyllotoxin derivative VP 16-213Cancer Chemotherapy and Pharmacology, 1979
- Etoposide (VP-16-213)Cancer Treatment Reviews, 1979
- VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.1978
- VM 26 and VP 16–213: A comparative analysisCancer, 1977
- Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivativesEuropean Journal of Cancer (1965), 1975
- EPEG, a new antineoplastic epipodophyllotoxinClinical Pharmacology & Therapeutics, 1975
- Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumorsEuropean Journal of Cancer (1965), 1973